VBI Vaccines, Inc. - Ordinary Shares (VBIV): Price and Financial Metrics
VBIV Price/Volume Stats
| Current price | $0.63 | 52-week high | $3.53 |
| Prev. close | $0.63 | 52-week low | $0.45 |
| Day low | $0.61 | Volume | 163,500 |
| Day high | $0.65 | Avg. volume | 383,000 |
| 50-day MA | $0.62 | Dividend yield | N/A |
| 200-day MA | $0.79 | Market Cap | 18.02M |
VBIV Stock Price Chart Interactive Chart >
VBI Vaccines, Inc. - Ordinary Shares (VBIV) Company Bio
VBI Vaccines Inc. develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Latest VBIV News From Around the Web
Below are the latest news stories about VBI VACCINES INC that investors may wish to consider to help them evaluate VBIV as an investment opportunity.
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingCAMBRIDGE, Mass., November 20, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients, were highlighted in a poster presentation at the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SN |
VBI Vaccines Reports Third Quarter 2023 Financial ResultsCAMBRIDGE, Mass., November 14, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023. |
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramCAMBRIDGE, Mass., October 26, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company’s current proprietary eVLP technology by coding the particles in messenger RNA (mRNA). In preclinical studies, VBI’s new mRNA-launched eVLP (MLE) technology has dem |
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of ConcernCAMBRIDGE, Mass., September 27, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 1 clinical study of its multivalent pan-coronavirus vaccine candidate, VBI-2901, which expresses the ancestral COVID-19, SARS, and MERS spike antigens. The Phase 1 clinical study enrolled 101 adults, aged 18-64 years who had received either two or three doses of a |
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMCAMBRIDGE, Mass., September 07, 2023--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM). The study will assess the safety, tolerability, tumor response rates, and survival following tre |
VBIV Price Returns
| 1-mo | 9.57% |
| 3-mo | 3.11% |
| 6-mo | 21.43% |
| 1-year | -79.48% |
| 3-year | -99.20% |
| 5-year | -98.93% |
| YTD | 7.23% |
| 2023 | -94.99% |
| 2022 | -83.29% |
| 2021 | -14.91% |
| 2020 | 99.28% |
| 2019 | -13.75% |
Continue Researching VBIV
Here are a few links from around the web to help you further your research on VBI Vaccines Inc's stock as an investment opportunity:VBI Vaccines Inc (VBIV) Stock Price | Nasdaq
VBI Vaccines Inc (VBIV) Stock Quote, History and News - Yahoo Finance
VBI Vaccines Inc (VBIV) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...